...
首页> 外文期刊>Bone marrow transplantation >How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT
【24h】

How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT

机译:同种异体造血干细胞移植后如何处理高血糖/移植后糖尿病

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients frequently develop glucose intolerance and post-transplant diabetes mellitus (PTDM). The clinical importance of PTDM and its detrimental impact on HSCT outcomes are under-recognized. After allo-HSCT, various mechanisms can contribute to the development of PTDM. Here we review information about hyperglycemia and PTDM after allo-HSCT as well as PTDM after solid organ transplantation and describe ways to manage hyperglycemia/PTDM after allogeneic HSCT. Taking into consideration a lack of well-established evidence in the field of allo-HSCT, more studies should be conducted in the future, which will require closer multidisciplinary collaboration between hematologists, endocrinologists and nutritionists.
机译:同种异体造血干细胞移植(allo-HSCT)接受者经常发展为葡萄糖耐受不良和移植后糖尿病(PTDM)。 PTDM的临床重要性及其对HSCT结局的不利影响尚未得到充分认识。继异基因造血干细胞移植之后,各种机制可以促进PTDM的发展。在这里,我们回顾了同种异体造血干细胞移植后的高血糖和PTDM以及实体器官移植后的PTDM的信息,并描述了异体造血干细胞移植后管理高血糖/ PTDM的方法。考虑到同种异体造血干细胞移植领域缺乏公认的证据,将来应进行更多研究,这需要血液学家,内分泌学家和营养学家之间更紧密的多学科合作。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号